A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca

Código QR

A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca

Gary W Jerkins,1 Guruprasad R Pattar,2 Shane R Kannarr3 1Advancing Vision Research, Nashville, TN, USA; 2The Eye Care Institute, Louisville, KY, USA; 3Kannarr Eye Care, Pittsburg, KS, USACorrespondence: Gary W JerkinsAdvancing Vision Associates, 4306 Harding Pike, Nashville, TN 37205, USATel +1 615...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jerkins GW, Pattar GR, Kannarr SR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	cyclosporine a keratoconjunctivitis sicca emulsion nanomicelles otx-101 Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/6acca0bd8bf949c6aafde28f313d065a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments
por: Periman LM, et al.
Publicado: (2020)

Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
por: Sheppard J, et al.
Publicado: (2021)

Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program
por: Pisella P, et al.
Publicado: (2018)

Practical guidance for the use of cyclosporine ophthalmic solutions in the management of dry eye disease
por: de Oliveira RC, et al.
Publicado: (2019)

Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease
por: Burade V, et al.
Publicado: (2020)

Dry Eye Syndrome and Sicca Complex are Commonly Found in Patients with Postural Orthostatic Tachycardia Syndrome
por: Ho DS, et al.
Publicado: (2020)

Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy
por: Nebbioso M, et al.
Publicado: (2019)

Managing Dry Eye Disease and Facilitating Realistic Patient Expectations: A Review and Appraisal of Current Therapies
por: Shen Lee B, et al.
Publicado: (2020)

Comparison of 0.2% and 0.18% hyaluronate eye drops in patients with moderate to severe dry eye with keratitis or keratoconjunctivitis
por: Groß D, et al.
Publicado: (2017)

Acupuncture and dry eye: current perspectives. A double-blinded randomized controlled trial and review of the literature
por: Dhaliwal DK, et al.
Publicado: (2019)

Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis
por: Shoughy SS, et al.
Publicado: (2016)

A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease
por: Friedman NJ, et al.
Publicado: (2016)

Vernal keratoconjunctivitis
por: Addis H, et al.
Publicado: (2018)

Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
por: White DE, et al.
Publicado: (2019)

Effect of topical Mitomycin-C (0.01%) in treatment of severe vernal refractory keratoconjunctivitis
por: SMH Emad, et al.
Publicado: (2005)

Epidemic Keratoconjunctivitis-Causing Adenoviruses Induce MUC16 Ectodomain Release To Infect Ocular Surface Epithelial Cells
por: Balaraj B. Menon, et al.
Publicado: (2016)

Topical Cyclosporine in Oral Lichen Planus—A Series of 21 Open-Label, Biphasic, Single-Patient Observations
por: Babak Monshi, et al.
Publicado: (2021)

Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions
por: Labib BA, et al.
Publicado: (2020)

Clinical and virological analysis of epidemic keratoconjunctivitis caused by adenovirus type 54 in a regional ophthalmic clinic in Kyushu, Japan
por: Uemura T, et al.
Publicado: (2018)

Sequential Keraring implantation and corneal cross-linking for the treatment of keratoconus in children with vernal keratoconjunctivitis
por: Abozaid MA
Publicado: (2017)

COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
por: Hassan Sajjad Rathore, et al.
Publicado: (2021)

The role of inflammation and antiinflammation therapies in keratoconjunctivitis sicca
por: Koray Gumus, et al.
Publicado: (2008)

Dry Eye Treatment with Topical Cyclosporine 0.1% in Chondroitin Sulfate Ophthalmic Emulsion
por: Matossian C, et al.
Publicado: (2021)

Effectiveness of Subconjunctival Cyclosporine in Treatment of Acute Allergic Conjunctivitis in a Rat-Model
por: Awara A, et al.
Publicado: (2020)

Remission of Kimura Disease With Carotid Hypervascularization After Cyclosporine Treatment
por: Severino Persechino, et al.
Publicado: (2020)

Clinical utility of cyclosporine (CsA) ophthalmic emulsion 0.05% for symptomatic relief in people with chronic dry eye: a review of the literature
por: Rhee MK, et al.
Publicado: (2017)

Cyclosporine A micellar delivery system for dry eyes
por: Kang H, et al.
Publicado: (2016)

Effect of Erythromycin on the Intestinal Transport of Cyclosporine
por: P Zakeri Milani,, et al.
Publicado: (2009)

Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye
por: Deveney T, et al.
Publicado: (2018)

Historia del manejo de rinitis atrófica
por: Burgos C,Ariel, et al.
Publicado: (2020)

Pharmacokinetic Disposition Difference Between Cyclosporine and Voclosporin Drives Their Distinct Efficacy and Safety Profiles in Clinical Studies
por: Li Y, et al.
Publicado: (2020)

Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management
por: Dodi PL
Publicado: (2015)

The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye
por: Stonecipher KG, et al.
Publicado: (2016)

Febrile Ulceronecrotic Mucha-Habermann Disease: A Rare Case Report and Review of Cases Treated With Oral Cyclosporine
por: Apasee Sooksamran, et al.
Publicado: (2021)

Cyclosporine Biosynthesis in <italic toggle="yes">Tolypocladium inflatum</italic> Benefits Fungal Adaptation to the Environment
por: Xiuqing Yang, et al.
Publicado: (2018)

Cyclosporine A Induces Cardiac Developmental Toxicity in Zebrafish by Up-Regulation of Wnt Signaling and Oxidative Stress
por: Mengqi Wan, et al.
Publicado: (2021)

Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study
por: Rush SW, et al.
Publicado: (2021)

A phase 1, open-label, single-arm study evaluating the ocular safety of OTX-101 and systemic absorption of cyclosporine in healthy human volunteers
por: Karpecki PM, et al.
Publicado: (2019)

Long-term efficacy and safety of infliximab and cyclosporine combination therapy for refractory uveoretinitis in Behçet’s disease
por: Katsuyama A, et al.
Publicado: (2019)

Síndrome de Sjögren: Caso clínico
por: Ladino R,Mabel, et al.
Publicado: (2015)